Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Guardant Health, Inc.GH · Entity 3238 | Chief Technology Officer | October 01, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Guardant Health, Inc.
Report date October 01, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 74,348 |
Ending reported balance
After 2026-10-01 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-10-01 · Exercise / conversion · Acquired 1,340 · Balance 71,975 Row 2 · 2026-10-01 · Exercise / conversion · Acquired 1,668 · Balance 73,643 Row 3 · 2026-10-01 · Exercise / conversion · Acquired 3,324 · Balance 76,967 Row 4 · 2026-10-01 · Exercise / conversion · Acquired 1,701 · Balance 78,668 Row 5 · 2026-10-01 · Tax withholding · Disposed 4,320 · Balance 74,348 F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-10-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-10-01 · Exercise / conversion · Disposed 1,340 · Balance 0 F2: This represents a restricted stock unit award granted on November 7, 2022 that vested over a four-year period. 25% of the shares subject to such award vested on October 1, 2023 and the remaining 75% of the shares vested in equal quarterly installments over the remaining three-year period thereafter. F3: Not applicable for Restricted Stock Units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-10-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-10-01 · Exercise / conversion · Disposed 1,668 · Balance 0 F4: This represents a restricted stock unit award granted on December 13, 2023 that vested over a three-year period. 33% of the shares subject to such award vested on October 1, 2024 and the remaining 67% of the shares vested in equal quarterly installments over the remaining two-year period thereafter. F3: Not applicable for Restricted Stock Units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 13,296 |
Reported balance
After 2026-10-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-10-01 · Exercise / conversion · Disposed 3,324 · Balance 13,296 F5: This represents a restricted stock unit award granted on November 8, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3: Not applicable for Restricted Stock Units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 10,202 |
Reported balance
After 2026-10-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-10-01 · Exercise / conversion · Disposed 1,701 · Balance 10,202 F6: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on April 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3: Not applicable for Restricted Stock Units. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.
F2: This represents a restricted stock unit award granted on November 7, 2022 that vested over a four-year period. 25% of the shares subject to such award vested on October 1, 2023 and the remaining 75% of the shares vested in equal quarterly installments over the remaining three-year period thereafter.
F3: Not applicable for Restricted Stock Units.
F4: This represents a restricted stock unit award granted on December 13, 2023 that vested over a three-year period. 33% of the shares subject to such award vested on October 1, 2024 and the remaining 67% of the shares vested in equal quarterly installments over the remaining two-year period thereafter.
F5: This represents a restricted stock unit award granted on November 8, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
F6: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on April 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2023 Filed Sep 5, 2023 20:59 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCOMMON STOCK | 110 | $35.01 | $3,851.10 |
DisclosureSEC source: 0001576280-23-000143 · wk-form4_1693947557.xml · nonDerivative · entry 6 Chudova Darya · CIK 0001977179 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,778 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| September 01, 2023 Filed Sep 5, 2023 20:59 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 316 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-23-000143 · wk-form4_1693947557.xml · nonDerivative · entry 5 Chudova Darya · CIK 0001977179 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,888 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2023 Filed Aug 8, 2023 21:13 UTC | Guardant Health, Inc. GH · Entity 3238 | GrantRESTRICTED STOCK UNITS · Derivative | 34,821 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-23-000129 · wk-form4_1691529181.xml · derivative · entry 2 Chudova Darya · CIK 0001977179 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,821 Underlying: COMMON STOCK · 34,821 shares Expires not disclosed F2 · derivative.exercise_date: This represents a restricted stock unit award granted on August 7, 2023 and vests over a four-year period. 25% of the shares subject to such award vests on the one-year anniversary of May 15, 2023, and the remaining 75% vests annually during the three-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| August 07, 2023 Filed Aug 8, 2023 21:13 UTC | Guardant Health, Inc. GH · Entity 3238 | GrantSTOCK OPTION (RIGHT TO BUY) · Derivative | 52,232 | $0.00 Strike: $37.50 | $0.00 |
DisclosureSEC source: 0001576280-23-000129 · wk-form4_1691529181.xml · derivative · entry 1 Chudova Darya · CIK 0001977179 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,232 Underlying: COMMON STOCK · 52,232 shares Expires 2033-08-07 F1 · derivative.exercise_date: The stock option granted on August 7, 2023 vests over a four-year period. 25% of the shares subject to such award will vest on the one-year anniversary of May 3, 2023 and the remaining 75% vests monthly for the three-year period thereafter. Read SEC document |
| August 01, 2023 Filed Sep 5, 2023 20:59 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRESTRICTED STOCK UNITS · Derivative | 1,440 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-23-000143 · wk-form4_1693947557.xml · derivative · entry 8 Chudova Darya · CIK 0001977179 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: COMMON STOCK · 1,440 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The restricted stock unit award was granted on August 1, 2019, of which 1,440 shares were outstanding on May 3, 2023, when elected as an executive officer. These shares will vest on August 1, 2023. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| August 01, 2023 Filed Sep 5, 2023 20:59 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCOMMON STOCK | 498 | $38.00 | $18,921.51 |
DisclosureSEC source: 0001576280-23-000143 · wk-form4_1693947557.xml · nonDerivative · entry 4 Chudova Darya · CIK 0001977179 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,572 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| August 01, 2023 Filed Sep 5, 2023 20:59 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 1,440 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-23-000143 · wk-form4_1693947557.xml · nonDerivative · entry 3 Chudova Darya · CIK 0001977179 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,070 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2023 Filed Sep 5, 2023 20:59 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRESTRICTED STOCK UNITS · Derivative | 316 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-23-000143 · wk-form4_1693947557.xml · derivative · entry 7 Chudova Darya · CIK 0001977179 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,841 Underlying: COMMON STOCK · 316 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock unit award was granted on November 2, 2021, of which 3,157 shares are outstanding on May 3, 2023, when elected as an executive officer. These shares vest in equal quarterly installments on the anniversary of 9/1/2022, and fully vested on 9/1/2025. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| June 01, 2023 Filed Sep 5, 2023 20:59 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCOMMON STOCK | 110 | $31.39 | $3,452.90 |
DisclosureSEC source: 0001576280-23-000143 · wk-form4_1693947557.xml · nonDerivative · entry 2 Chudova Darya · CIK 0001977179 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,630 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| June 01, 2023 Filed Sep 5, 2023 20:59 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 316 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-23-000143 · wk-form4_1693947557.xml · nonDerivative · entry 1 Chudova Darya · CIK 0001977179 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,740 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.